TAM receptors Tyro3 and Mer as novel targets in colorectal cancer

CRC remains the third most common cancer worldwide with a high 5-year mortality rate in advanced cases. Combined with chemotherapy, targeted therapy is an additional treatment option. However as CRC still escapes targeted therapy the vigorous search for new targets is warranted to increase patients´...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schmitz, Robin (VerfasserIn) , Freire Valls, Aida (VerfasserIn) , Yerbes, Rosario (VerfasserIn) , Richter, Sophie von (VerfasserIn) , Kahlert, Christoph (VerfasserIn) , Loges, Sonja (VerfasserIn) , Weitz, Jürgen (VerfasserIn) , Schneider, Martin (VerfasserIn) , Ruiz de Almodóvar, Carmen (VerfasserIn) , Ulrich, Alexis (VerfasserIn) , Schmidt, Thomas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 28, 2016
In: OncoTarget
Year: 2016, Jahrgang: 7, Heft: 35, Pages: 56355-56370
ISSN:1949-2553
DOI:10.18632/oncotarget.10889
Online-Zugang:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.18632/oncotarget.10889
Verlag, lizenzpflichtig, Volltext: https://www.oncotarget.com/article/10889/text/
Volltext
Verfasserangaben:Robin Schmitz, Aida Freire Valls, Rosario Yerbes, Sophie von Richter, Christoph Kahlert, Sonja Loges, Jürgen Weitz, Martin Schneider, Carmen Ruiz de Almodovar, Alexis Ulrich, Thomas Schmidt
Beschreibung
Zusammenfassung:CRC remains the third most common cancer worldwide with a high 5-year mortality rate in advanced cases. Combined with chemotherapy, targeted therapy is an additional treatment option. However as CRC still escapes targeted therapy the vigorous search for new targets is warranted to increase patients´ overall survival.
Beschreibung:Gesehen am 19.05.2020
Beschreibung:Online Resource
ISSN:1949-2553
DOI:10.18632/oncotarget.10889